(Total Views: 937)
Posted On: 04/04/2022 10:56:56 PM
Post# of 154078
I wouldn't quite call it a "good" summary, Aero, because the writer didn't mention why Cytodyn had a "poor clinical trial design."
A "good" summary of Leronlimab in 2020/2021 would have noted how the FDA limited our extraordinarily safe molecule to just a 2 dose regimen, not the requested 4. And it could have also mentioned how t- somehow - Leronlimab got many more elderly patients than the control arm. And had this not been the case, we quite likely would have achieved stat significance. There's also our NEWS2 success, but once again, not recognized by the FDA.
Bottom line, Remdesivir kills and Leronlimab saves, so it's no surprise which one the FDA rewarded with an EUA.
I suspect we're all tired of hearing about this, but we must never forget.
A "good" summary of Leronlimab in 2020/2021 would have noted how the FDA limited our extraordinarily safe molecule to just a 2 dose regimen, not the requested 4. And it could have also mentioned how t- somehow - Leronlimab got many more elderly patients than the control arm. And had this not been the case, we quite likely would have achieved stat significance. There's also our NEWS2 success, but once again, not recognized by the FDA.
Bottom line, Remdesivir kills and Leronlimab saves, so it's no surprise which one the FDA rewarded with an EUA.
I suspect we're all tired of hearing about this, but we must never forget.
(11)
(0)
